Paul A Lapchak

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi 3alpha-OL-5-beta-pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: synergism with tissue plasminogen activator
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, 9500 Gilman Drive, MTF 316, La Jolla, 92093 0624, USA
    Exp Neurol 197:531-7. 2006
  2. ncbi Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: a combination therapy study with tissue plasminogen activator
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093 062, USA
    Brain Res 1309:136-45. 2010
  3. ncbi The phenylpropanoid micronutrient chlorogenic acid improves clinical rating scores in rabbits following multiple infarct ischemic strokes: synergism with tissue plasminogen activator
    Paul A Lapchak
    University of California San Diego, Department of Neuroscience, 9500 Gilman Drive MTF316, La Jolla, CA 92093 0624, USA
    Exp Neurol 205:407-13. 2007
  4. ncbi Advances in ischemic stroke treatment: neuroprotective and combination therapies
    Paul A Lapchak
    Stroke Research Scientist, University of California San Diego, Department of Neuroscience, La Jolla, CA 92093 0624, USA
    Expert Opin Emerg Drugs 12:97-112. 2007
  5. ncbi Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, 9500 Gilman Drive MTF316, La Jolla, CA 92093 0624, USA
    Brain Res 1088:141-7. 2006
  6. ncbi Pharmacology of caffeinol in embolized rabbits: clinical rating scores and intracerebral hemorrhage incidence
    Paul A Lapchak
    University of California San Diego, Department of Neuroscience, La Jolla 92093 0624, USA
    Exp Neurol 188:286-91. 2004
  7. ncbi Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores
    Paul A Lapchak
    University of California San Diego, Department of Neuroscience, La Jolla 92093 0624, USA
    Exp Neurol 188:279-85. 2004
  8. ncbi Transcranial infrared laser therapy improves clinical rating scores after embolic strokes in rabbits
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, MTF 316, 9500 Gilman Drive, La Jolla, CA 92093 0624, USA
    Stroke 35:1985-8. 2004
  9. ncbi Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of ischemic stroke
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, La Jolla, California 92093 0624, USA
    Am J Cardiovasc Drugs 3:87-94. 2003
  10. ncbi Tumor necrosis factor-alpha is involved in thrombolytic-induced hemorrhage following embolic strokes in rabbits
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, La Jolla, CA 92093 0624, USA
    Brain Res 1167:123-8. 2007

Detail Information

Publications44

  1. ncbi 3alpha-OL-5-beta-pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: synergism with tissue plasminogen activator
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, 9500 Gilman Drive, MTF 316, La Jolla, 92093 0624, USA
    Exp Neurol 197:531-7. 2006
    ....
  2. ncbi Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: a combination therapy study with tissue plasminogen activator
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093 062, USA
    Brain Res 1309:136-45. 2010
    ..Moreover, it appears that TSC can be administered with tPA, since the combination did not result in any significant change in intracerebral hemorrhage incidence...
  3. ncbi The phenylpropanoid micronutrient chlorogenic acid improves clinical rating scores in rabbits following multiple infarct ischemic strokes: synergism with tissue plasminogen activator
    Paul A Lapchak
    University of California San Diego, Department of Neuroscience, 9500 Gilman Drive MTF316, La Jolla, CA 92093 0624, USA
    Exp Neurol 205:407-13. 2007
    ..The results show that the therapeutic window for a standard effective dose of tPA could be increased by administration of CGA, suggesting that it may be most useful as a co-therapy with a standard thrombolytic treatment regimen...
  4. ncbi Advances in ischemic stroke treatment: neuroprotective and combination therapies
    Paul A Lapchak
    Stroke Research Scientist, University of California San Diego, Department of Neuroscience, La Jolla, CA 92093 0624, USA
    Expert Opin Emerg Drugs 12:97-112. 2007
    ..Ideally, a successful combination of neuroprotectant (drug or device) and thrombolytic therapy for stroke would minimize the side effects of thrombolysis followed by supplementary neuroprotection thereafter...
  5. ncbi Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, 9500 Gilman Drive MTF316, La Jolla, CA 92093 0624, USA
    Brain Res 1088:141-7. 2006
    ....
  6. ncbi Pharmacology of caffeinol in embolized rabbits: clinical rating scores and intracerebral hemorrhage incidence
    Paul A Lapchak
    University of California San Diego, Department of Neuroscience, La Jolla 92093 0624, USA
    Exp Neurol 188:286-91. 2004
    ....
  7. ncbi Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores
    Paul A Lapchak
    University of California San Diego, Department of Neuroscience, La Jolla 92093 0624, USA
    Exp Neurol 188:279-85. 2004
    ..In addition, the study shows that NXY-059 can be administered in combination with tenecteplase to provide additional behavioral improvement at extended delays following embolization...
  8. ncbi Transcranial infrared laser therapy improves clinical rating scores after embolic strokes in rabbits
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, MTF 316, 9500 Gilman Drive, La Jolla, CA 92093 0624, USA
    Stroke 35:1985-8. 2004
    ..Because photon energy delivered using a low-energy infrared laser may be useful to treat stroke, we determined whether transcranial laser therapy would improve behavioral deficits in a rabbit small clot embolic stroke model (RSCEM)...
  9. ncbi Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of ischemic stroke
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, La Jolla, California 92093 0624, USA
    Am J Cardiovasc Drugs 3:87-94. 2003
    ..The tolerability of argatroban in patients with acute stroke is currently being assessed in the multicenter Argatroban in Ischemic Stroke (ARGIS-1) trial...
  10. ncbi Tumor necrosis factor-alpha is involved in thrombolytic-induced hemorrhage following embolic strokes in rabbits
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, La Jolla, CA 92093 0624, USA
    Brain Res 1167:123-8. 2007
    ....
  11. ncbi Transcranial near-infrared light therapy improves motor function following embolic strokes in rabbits: an extended therapeutic window study using continuous and pulse frequency delivery modes
    P A Lapchak
    University of California San Diego, Department of Neuroscience, MTF 316, 9500 Gilman Drive, La Jolla, CA 92093 0624, USA
    Neuroscience 148:907-14. 2007
    ..The results show that P mode NILT can result in significant clinical improvement when administered 6 h following embolic strokes in rabbits and should be considered for clinical development...
  12. ncbi Advances in hemorrhagic stroke therapy: conventional and novel approaches
    Paul A Lapchak
    University of California San Diego, Department of Neuroscience, MTF 316, 9500 Gilman Drive, La Jolla, CA 92093 0624, USA
    Expert Opin Emerg Drugs 12:389-406. 2007
    ....
  13. ncbi Transcranial near infrared laser treatment (NILT) increases cortical adenosine-5'-triphosphate (ATP) content following embolic strokes in rabbits
    Paul A Lapchak
    University of California San Diego, Department of Neuroscience, 9500 Gilman Drive MTF316, La Jolla, CA 92093 0624, USA
    Brain Res 1306:100-5. 2010
    ..The data provide new insight into the molecular mechanisms associated with clinical improvement following NILT...
  14. ncbi The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, 9500 Gilman Drive MTF316, La Jolla, CA 92093 0624, USA
    Brain Res 1303:144-50. 2009
    ..Based upon our results, patients on simvastatin treatment may have significantly reduced tPA-induced side effects should they require tPA administration following an embolic stroke...
  15. ncbi Effect of internal carotid artery reperfusion in combination with Tenecteplase on clinical scores and hemorrhage in a rabbit embolic stroke model
    Paul A Lapchak
    University of California San Diego, Department of Neuroscience, MTF 316, 9500 Gilman Drive, La Jolla, CA 92093 0624, USA
    Brain Res 1294:211-7. 2009
    ..However, TNK administration significantly increased behavioral outcome when given 2 h following embolization; an increase that is not affected by combining TNK with REP...
  16. ncbi The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator
    Paul A Lapchak
    University of California San Diego, Department of Neuroscience, 9500 Gilman Drive MTF316, La Jolla, CA 92093 0624, USA
    Exp Neurol 215:95-100. 2009
    ..Edaravone can also be administered with a thrombolytic to improve behavior...
  17. ncbi Therapeutic window for nonerythropoietic carbamylated-erythropoietin to improve motor function following multiple infarct ischemic strokes in New Zealand white rabbits
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, La Jolla, CA 92093 0624, USA
    Brain Res 1238:208-14. 2008
    ..Our results suggest that CEPO may be useful to treat acute ischemic stroke and supports the study of CEPO in stroke patients...
  18. ncbi Safety profile of transcranial near-infrared laser therapy administered in combination with thrombolytic therapy to embolized rabbits
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, La Jolla, CA 92093 0624, USA
    Stroke 39:3073-8. 2008
    ..The purpose for this study is to determine if the combination of TLT and thrombolysis should be investigated further in a human clinical trial...
  19. ncbi Carbamylated erythropoietin to treat neuronal injury: new development strategies
    Paul A Lapchak
    University of California San Diego, Department of Neurosciences, MTF 316, 9500 Gilman Drive, La Jolla, CA 92093 0624, USA
    Expert Opin Investig Drugs 17:1175-86. 2008
    ..It is a potentially important pharmacological agent that may be applied to the treatment of several diseases affecting central and peripheral system neurons...
  20. ncbi Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes
    P A Lapchak
    University of California, San Diego, Department of Neuroscience, La Jolla, CA 92093 0624, USA
    Neuroscience 150:585-91. 2007
    ..The results suggest that baicalein, or derivatives of baicalein with multiple pharmacological activities may be useful to develop as novel treatments for acute ischemic stroke...
  21. ncbi The neuroactive steroid 3-alpha-ol-5-beta-pregnan-20-one hemisuccinate, a selective NMDA receptor antagonist improves behavioral performance following spinal cord ischemia
    P A Lapchak
    Department of Neuroscience, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0624, USA
    Brain Res 997:152-8. 2004
    ....
  22. ncbi Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, La Jolla, CA 92093 0624, USA
    Exp Neurol 185:154-9. 2004
    ..Our preclinical studies suggest that Tenecteplase has a better pharmacological profile than Alteplase and supports further investigation of Tenecteplase in randomized double-blinded clinical trials in stroke patients...
  23. ncbi Prosaptide exacerbates ischemia-induced behavioral deficits in vivo; an effect that does not involve mitogen-activated protein kinase activation
    P A Lapchak
    University of California San Diego, Department of Neuroscience, MTF 316, 9500 Gilman Drive, La Jolla CA 92093 0624, USA
    Neuroscience 101:811-4. 2000
    ..4,14,16,18) Our results show not only that prosaptide was not neurotrophic/neuroprotectant in vivo, but rather it worsened ischemia-induced behavioral deficits...
  24. ncbi Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia
    P A Lapchak
    Department of Neuroscience, University of California at San Diego, La Jolla, CA 92093 0624, USA
    Stroke 32:1220-5. 2001
    ..The present study evaluated the pharmacological effects of a specific long-acting COX-2 inhibitor, SC-236, in a reversible rabbit spinal cord ischemia model using clinical rating scores (behavioral analysis) as the primary end point...
  25. ncbi Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke
    P A Lapchak
    Department of Neuroscience, University of California at San Diego, La Jolla 92093 0624, USA
    Stroke 31:3034-40. 2000
    ....
  26. ncbi Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents
    P A Lapchak
    Department of Neuroscience, University of California San Diego, La Jolla, California 92093 0624, USA
    CNS Drugs 15:819-29. 2001
    ..Overall, preclinical studies indicate that MMP inhibition or free radical scavenging in combination with alteplase may circumvent the high risk of haemorrhaging with alteplase...
  27. ncbi Dehydroepiandrosterone sulfate is neuroprotective in a reversible spinal cord ischemia model: possible involvement of GABA(A) receptors
    P A Lapchak
    University of California San Diego, Department of Neuroscience, La Jolla, CA 92093 0624, USA
    Stroke 31:1953-6; discussion 1957. 2000
    ..The present study evaluated the pharmacological effects of DHEAS in a reversible spinal cord ischemia model...
  28. ncbi The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke
    Paul A Lapchak
    Department of Neuroscience, University of California at San Diego, La Jolla 92093 0624, USA
    Stroke 33:147-52. 2002
    ....
  29. ncbi Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment
    Paul A Lapchak
    Department of Neuroscience, University of California, San Diego, 9500 Gilman Drive, MTF316, La Jolla, CA 92093 0624, USA
    Curr Neurol Neurosci Rep 2:38-43. 2002
    ..Although these drugs affect different mechanisms, the common denominator seemed to be their effectiveness in reducing the incidence of hemorrhage in response to thrombolytic infusion following an embolic stroke...
  30. ncbi Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator
    Paul A Lapchak
    Department of Neuroscience, University of California at San Diego, La Jolla, CA 92093 0624, USA
    Stroke 33:1411-5. 2002
    ..Thus, we determined the effects of NXY-059G, a generic form of NXY-059, on behavioral outcome after an embolic stroke when administered alone or in combination with tPA...
  31. ncbi Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator
    Paul A Lapchak
    Department of Neuroscience, University of California at San Diego, La Jolla 92093 0624, USA
    Stroke 33:1665-70. 2002
    ..In addition, we determined whether NXY-059G affected 2 physiological variables, blood glucose levels and body temperature...
  32. ncbi Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits
    Paul A Lapchak
    Department of Neuroscience, University of California at San Diego, La Jolla, CA 92093 0624, USA
    Stroke 33:2279-84. 2002
    ....
  33. ncbi Development of thrombolytic therapy for stroke: a perspective
    Paul A Lapchak
    University of California San Diego, Department of Neuroscience, 9500 Gilman Drive, La Jolla, CA 92093 0624, USA
    Expert Opin Investig Drugs 11:1623-32. 2002
    ..These important areas of drug discovery and development will be reviewed...
  34. ncbi Effects of intrathecal administration of a cell permeant caspase inhibitor, boc-D-fluoromethylketone (BDFMK), on behavioral deficits following spinal cord ischemia: a dose-response analysis
    Paul A Lapchak
    University of California San Diego, Department of Neuroscience, La Jolla, CA 92093 0624, USA
    Brain Res 959:183-90. 2003
    ..Our results suggest that administration of a single dose of the caspase inhibitor BDFMK is insufficient to attenuate ischemia-induced behavioral deficits following aortic occlusion...
  35. ncbi NXY-059. Centaur
    Paul A Lapchak
    UCSD Neuroscience MTF 316, 9500 Gilman Drive, La Jolla, CA 92093 0624, USA
    Curr Opin Investig Drugs 3:1758-62. 2002
    ..Phase II clinical trials are ongoing, with phase III trials in acute stroke planned for initiation in early 2003...
  36. ncbi Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator
    Paul A Lapchak
    University of California San Diego, Department of Neuroscience, MTF 316, 9500 Gilman Dr, La Jolla, Calif 92093 0624, USA
    Stroke 34:2013-8. 2003
    ..Therefore, we determined the effects of ebselen when administered alone or with the thrombolytic tissue plasminogen activator (tPA), the only Food and Drug Administration-approved pharmacological agent for the treatment of stroke...
  37. ncbi Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke
    Paul A Lapchak
    Department of Neuroscience, University of California San Diego, La Jolla, CA 92093 0624, USA
    CNS Drug Rev 9:253-62. 2003
    ..In addition, NXY-059 may represent a useful adjunct stroke therapy to tPA, since preclinical studies have demonstrated that NXY-059 increases the therapeutic window for tPA and lowers the occurrence of tPA-induced ICH...
  38. ncbi Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6, 6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator
    P A Lapchak
    Department of Neuroscience, University of California at San Diego, La Jolla, CA 92093 0624, USA
    Stroke 32:147-53. 2001
    ..We also compared the effects of PBN with those of 2,2,6, 6-tetramethylpiperidine-N:-oxyl (TEMPO), another spin trap agent that has a different chemical structure and trapping profile, on the incidence of infarcts and hemorrhage...
  39. ncbi A novel approach to screening for new neuroprotective compounds for the treatment of stroke
    Pamela Maher
    The Salk Institute for Biological Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037, USA
    Brain Res 1173:117-25. 2007
    ..Fisetin significantly reduced the behavioral deficits following a stroke, providing proof of principle for this novel approach to identifying new compounds for the treatment of stroke...
  40. ncbi Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model
    D F Chapman
    Department of Neurosciences, University of California at San Diego School of Medicine, and Department of Neurology, Veterans Administration Medical Center, San Diego, CA, USA
    Stroke 32:748-52. 2001
    ..These findings suggest that TNK shows promise as an alternative thrombolytic treatment for stroke, but we could not demonstrate improved safety compared with wild-type tPA...
  41. ncbi Comparison of the post-embolization effects of tissue-plasminogen activator and simvastatin on neurological outcome in a clinically relevant rat model of acute ischemic stroke
    Kama Z Guluma
    Department of Emergency Medicine, University of California San Diego Medical Center, San Diego, CA 92103 8676, USA
    Brain Res 1354:206-16. 2010
    ..These results suggest that more research needs to be done to fully ascertain the therapeutic potential and optimal dosing paradigm of a post-ischemic treatment with a statin...
  42. ncbi Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases
    P A Lapchak
    Amgen Inc, Department of Neuroscience, MC 5 1 C, 1840 de Havilland Drive, Thousand Oaks, CA 91320 1789, USA
    Cell Tissue Res 286:179-89. 1996
    ..This review presents a comprehensive survey of the recently described pharmacological activities of glial cell line-derived neurotrophic factor on the central nervous system...
  43. ncbi Preclinical development of neurosteroids as neuroprotective agents for the treatment of neurodegenerative diseases
    P A Lapchak
    Department of Neuroscience, University of California-San Diego, La Jolla, California 92093-0624, USA
    Int Rev Neurobiol 46:379-97. 2001
    ..2000), their potential therapeutic benefits may be extended to include the treatment of other neurodegenerative diseases not directly linked to excitotoxicity...
  44. ncbi Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection
    P A Lapchak
    Amgen Inc, Department of Neuroscience, Thousand Oaks, CA 91320, USA
    Brain Res 747:92-102. 1997
    ..These data support the potential effectiveness of intraventricular administered GDNF as a treatment for Parkinson's disease...